Sotac PharmaceuticalsNSE:SOTAC 52 ROA % is 3.95% as of Sep. 2025, which is 17% below its 10-year median of 4.78. GuruFocus rates NSE:SOTAC with a GF Score™ of 52/100 and a GF Value™ of ₹110.01 (Fairly Valued). The stock has 6 warning signs investors should review. Among 1,003 Drug Manufacturers companies, Sotac Pharmaceuticals ranks better than 72.38% on this metric.
ROA % is calculated as Net Income divided by its average Total Assets over a certain period of time. Sotac Pharmaceuticals's annualizedNet Income for the quarter that ended in Sep. 2025 was ₹48.9 Mil.
Sotac Pharmaceuticals's average Total Assets over the quarter that ended in Sep. 2025 was ₹1,238.0 Mil. Therefore, Sotac Pharmaceuticals's annualized ROA % for the quarter that ended in Sep. 2025 was 3.95%.
The historical rank and industry rank for Sotac Pharmaceuticals's ROA % or its related term are showing as below:
NSE:SOTAC'
s ROA % Range Over the Past 10 Years
Min: -7.27 Med: 4.78 Max: 7.07
Current: 7.07
During the past 6 years, Sotac Pharmaceuticals's highest ROA % was 7.07%. The lowest was -7.27%. And the median was 4.78%.
NSE:SOTAC's ROA % is ranked better than 72.38% of 1003
companies
in the Drug Manufacturers industry
Industry Median: 2.69
vs NSE:SOTAC: 7.07
ROA % measures the rate of return on the total assets (shareholder equity plus liabilities). It measures a firm's efficiency at generating profits from shareholders' equity plus its liabilities. ROA % shows how well a company uses what it has to generate earnings. ROA %s can vary drastically across industries. Therefore, ROA % should not be used to compare companies in different industries. For retailers, a ROA % of higher than 5% is expected. For example, Wal-Mart (WMT) has a ROA % of about 8% as of 2012. For banks, ROA % is close to their interest spread. A banks ROA % is typically well under 2%.
Similar to ROE, ROA % is affected by profit margins and asset turnover. This can be seen from the Du Pont Formula:
Note:
The Net Income data used here is two times the semi-annual (Sep. 2025) net income data. The Revenue data used here is two times the semi-annual (Sep. 2025) revenue data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Like ROE, ROA % is calculated with only 12 months data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. ROA % can be affected by events such as stock buyback or issuance, and by goodwill, a company's tax rate and its interest payment. ROA % may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high ROA % may indicate vulnerability in the durability of the competitive advantage.
E.g. Raising $43b to take on KO is impossible, but $1.7b to take on Moody's is. Although Moody's ROA % and underlying economics is far superior to Coca Cola, the durability is far weaker because of lower entry cost.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Sotac Pharmaceuticals's ROA %, along with its competitors' market caps and ROA % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sotac Pharmaceuticals ROA % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Sotac Pharmaceuticals's ROA % distribution charts can be found below:
* The bar in red indicates where Sotac Pharmaceuticals's ROA % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROA %, the net income of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is two times the semi-annual (Sep. 2025) net income data.
ROA % is displayed in the 30-year financial page.
Sotac Pharmaceuticals (NSE:SOTAC) has a ROA % of 3.95% as of Sep. 2025. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on Sotac Pharmaceuticals and its competitors. This is 17% below median its historical median of 4.78. According to the industry distribution chart, Sotac Pharmaceuticals ranks #277 out of 1003 companies in the Drug Manufacturers industry, placing it in the top 27.6%.
Is Sotac Pharmaceuticals' ROA % too high?
Sotac Pharmaceuticals' current ROA % of 3.95% is 17% below median its 10-year median of 4.78. The Drug Manufacturers industry median ROA % is 2.69. Sotac Pharmaceuticals' value of 3.95% is 46.8% above this industry median. Based on the distribution chart, Sotac Pharmaceuticals ranks #277 out of 1003 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Sotac Pharmaceuticals has a GF Score™ of 52/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Sotac Pharmaceuticals' ROA % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Sotac Pharmaceuticals ranks #277 out of 1003 companies for ROA %. This puts Sotac Pharmaceuticals in the upper half of its industry. The industry median ROA % is 2.69. Sotac Pharmaceuticals' value of 3.95% is 46.8% above this benchmark. While the company's 10-year median is 4.78 vs. the industry median of 2.69, Sotac Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROA % for a Drug Manufacturers company?
The median ROA % among Drug Manufacturers companies is 2.69, based on 1,003 companies in the industry. Companies in the top quartile (top 25%) have a ROA % significantly above this median, while those in the bottom quartile fall well below. However, ROA % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sotac Pharmaceuticals's current ROA % of 3.95% is 46.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROA % mean?
A high ROA % can signal that a stock is expensive relative to its fundamentals. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on Sotac Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median ROA % is 2.69 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sotac Pharmaceuticals's current ROA % is 3.95%, which is 17% below median its own 10-year median of 4.78. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sotac Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Sotac Pharmaceuticals (NSE:SOTAC) is currently considered Fairly Valued. The stock's GF Value™ is ₹110.01, compared to a current price of ₹105.00 — trading 4.6% below its estimated fair value. The current ROA % is 3.95%, which is 17% below median its 10-year median of 4.78 and 46.8% above the Drug Manufacturers industry median of 2.69. Sotac Pharmaceuticals' overall GF Score™ is 52/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROA % calculated?
ROA % is calculated from a company's financial statements. For Sotac Pharmaceuticals (NSE:SOTAC), the current ROA % is 3.95% as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sotac Pharmaceuticals (NSE:SOTAC) Overvalued in 2026?
Based on GuruFocus' analysis, Sotac Pharmaceuticals stock appears to be undervalued.
The current stock price of ₹105.00 is trading 4.6% below its estimated GF Value™ of ₹110.01.
GuruFocus considers Sotac Pharmaceuticals to be Fairly Valued.
Key valuation signals for NSE:SOTAC:
ROA %: 3.95% (17% below median its 10-year median of 4.78)
GF Value™: ₹110.01 vs. price of ₹105.00 (4.6% below fair value)
Industry Position: 46.8% above the Drug Manufacturers median (#277 of 1003)
No single metric tells the full story. See the NSE:SOTAC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sotac Pharmaceuticals Ltd operates chiefly in pharmaceutical manufacturing, serving a broad range of therapeutic segments including anti-diabetic, anti-psychotic, vitamins and minerals, anti-cold, anti-allergic, derma products, antacids, anti-ulcerants, cardiac, analgesic, anti-bacterial, anti-fungal, and more. The company manufactures tablets, capsules, syrups, and external preparations under contract manufacturing and loan licensing agreements, for domestic and international markets. Its clients include notable pharmaceutical marketers such as Cadila Pharma and Viatris. Revenue is distributed between domestic pharmaceutical product sales and international exports, supporting scalable growth across geographies.
52GF Score
Get the complete analysis for NSE:SOTAC
ROA % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:SOTAC has been successfully added to your 
